Historical CRT Devices
 

Historical CRT Devices

Cardiac resynchronization therapy (CRT) is a proven treatment for selected patients with heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction.

Concerto II CRT-D

concertoiicrtd

Concerto II CRT-D Device

A high-energy, wireless device with features that help to ensure CRT.

Key features include:

Important Safety Information

Changes in patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

Specifications
Volume 38 cc
Size (H x W x D 69 x 51 x 15 mm
Mass 68 g
Pace/sense ports Three IS-1 bipolar (A, RV, LV)
Defibrillation ports Two DF-1 (RV coil [HVB], SVC [HVX]
External shield Titanium
Radiopaque ID PUG
Battery Lithium silver vanadium oxide

References

  1. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
  2. Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
  3. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
  4. Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
  5. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
  6. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol. 15 No. 9 2009, p 813.
  7. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.

InSync Sentry CRT-D Device

InSync-Sentry-bth

InSync Sentry CRT-D Device

The world’s first device with OptiVol Fluid Status Monitoring provides proven cardiac resynchronization and ICD therapies.

Key features include:

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

Specifications
Volume 40 cc
Size (H x W x D 73 x 51 x 15 mm
Mass 78 g
Pace/sense ports Three IS-1 bipolar (A, RV, LV)
Defibrillation ports Two DF-1 (RV coil [HVB], SVC [HVX]
External shield Titanium
Radiopaque ID PRK
Battery Lithium silver vanadium oxide; 3.2 V nominal
 

References

  1. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
  2. Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
  3. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
  4. Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
  5. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
  6. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol. 15 No. 9 2009, p 813.
  7. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.
 

InSync Maximo CRT-D Device

InSync Maximo CRT-D Device

InSync Maximo CRT-D Device

Advanced cardiac resynchronization and ICD therapies combine with sophisticated anti-tachycardia pacing.

Key features include:

  • High defibrillation safety margin
  • Separately programmable ventricular outputs for adapting pacing outputs to patient needs
  • Sophisticated device diagnostics for help in assessing a patient’s clinical status
  • Remote device follow-up with the exclusive Medtronic CareLink® Network

Important Safety Information

Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

Mechanical Specifications

Volume 40 cc
Size (H x W x D 73 x 51 x 15 mm
Mass 78 g
Pace/sense ports Three IS-1 bipolar (A, RV, LV)
Defibrillation ports Two DF-1 (RV coil [HVB], SVC [HVX]
External shield Titanium
Radiopaque ID PRL
Battery Lithium silver vanadium oxide; 3.2 V nominal

InSync II Marquis CRT-D Device

InSync II Marquis CRT-D Device

InSync II Marquis CRT-D Device

Patient-tailored CRT options for heart failure management along with ICD protection.

Key features include:

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

Mechanical Specifications

Volume 38 cc
Size (H x W x D 73 x 51 x 14 mm
Mass 77 g
Pace/sense ports Three IS-1 bipolar (A, RV, LV)
Defibrillation ports Two DF-1 (RV coil [HVB], SVC [HVX]
External shield Titanium
Radiopaque ID PRJ
Battery Lithium silver vanadium oxide; 3.2 V nominal

References

  1. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. August 14, 2001;104:796-801.

InSync Marquis CRT-D Device

InSyncMarquis-bth

InSync Marquis CRT-D Device

Cardiac resynchronization and ICD therapies along with tools for efficient heart failure patient management.

Key features include:

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

Mechanical Specifications 

Volume38 cc
Size (H x W x D73 x 51 x 14 mm
Mass77 g
Pace/sense portsThree IS-1 bipolar (A, RV, LV)
Defibrillation portsTwo DF-1 (RV coil [HVB], SVC [HVX]
External shieldTitanium
Radiopaque IDPLT
BatteryLithium silver vanadium oxide; 3.2 V nominal

References

  1. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. August 14, 2001;104:796-801.

InSync III CRT-P Device

insynciiii

InSync III CRT-P Device

Cardiac resynchronization combined with bradycardia pacing therapy.

Key features:

  • Rate adaptive pacing
  • Dual chamber and atrial tracking modes
  • Heart failure management for patient assessment

 

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

 

Mechanical Specifications 

Volume 16 cc
Size (H x W x D 51 x 59 x 7 mm
Mass 26 g
Pace/sense ports Three IS-1 bipolar (A, RV, LV)
External shield Titanium
Radiopaque ID PKF
Battery Lithium-hybrid cathode
Last updated: 24 Jan 2012

Related Therapy

Heart Failure Management

Medtronic Fully Integrated CRT Implant System

Medtronic 24-hour Technical Support

(800) 328-2518